Couverture de Entrepreneur Rx

Entrepreneur Rx

Entrepreneur Rx

De : John Shufeldt MD JD MBA FACEP
Écouter gratuitement

Offres de saison | 0,99 € par mois pendant les 3 premiers mois

5,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
À propos de ce contenu audio
What does it take to build something that matters? Hosted by John Shufeldt, Entrepreneur Rx features conversations with founders, investors, executives, and innovators who are building the future. From entrepreneurship and venture capital to technology, healthcare, defense, and leadership, each episode explores the stories, challenges, and lessons behind creating impactful companies and driving meaningful change. Learn more at www.XcellerantVentures.comJohn Shufeldt, MD, JD, MBA, FACEP Direction Economie Management et direction
Épisodes
  • Jason Scherer: From Medical Device Idea to Market
    Nov 17 2026

    Why does it take so much time, money, and complexity to turn a good medical device idea into something physicians can actually use?

    In this episode of Entrepreneur Rx, host John Shufeldt sits down with Jason Scherer, Founder and CEO of Voltas, to explore what it really takes to bring a medical device from an idea on a napkin to a commercial product.

    Jason has spent nearly 20 years in the medical device industry, working across sales, commercialization, and company growth. Along the way, he helped bring more than 20 medical devices to market and was part of teams that ultimately experienced successful exits, including companies acquired by Johnson & Johnson.

    But the idea for Voltas came from Jason’s own experience as an inventor.

    After developing a medical device of his own, he found himself coordinating separate engineering, regulatory, coating, manufacturing, tooling, and sterilization partners, each with different priorities, timelines, and incentives. The process became expensive, fragmented, and difficult to manage.

    So he decided to build the company he wished had existed.

    Today, Voltas brings medical device development and manufacturing capabilities together under one roof, including engineering, prototyping, regulatory support, testing, tooling, manufacturing, assembly, sterilization, and commercialization. Jason shares how that integrated model can help inventors move more efficiently from concept to production while avoiding many of the mistakes he made himself.

    John and Jason also get practical about what physician inventors need to consider before pursuing a device. Is the problem meaningful enough to solve? Can the product actually be manufactured? Is it patentable? Is there reimbursement or a viable business model? And is the inventor willing to stay committed through years of iteration, setbacks, and capital requirements?

    They also look ahead at what Jason is seeing across the medical device pipeline, including the rise of sensor-based wearables, smaller catheter-based technologies, minimally invasive devices, and new challenges created by medicine in space.

    The conversation is a candid look at innovation from someone who has experienced the process from nearly every angle: selling medical devices, launching one himself, making expensive mistakes, and now helping other inventors turn their ideas into real products.

    About Jason Scherer: Jason Scherer is the Founder and CEO of Voltas and has nearly 20 years of experience in medical device sales and commercialization. He has been involved in bringing more than 20 medical devices to market and has helped build and scale companies through two successful exits. He founded Voltas after experiencing firsthand how fragmented the traditional medical device development process can be.

    About Voltas: Voltas is a vertically integrated medical device development and manufacturing company based in Minnesota. The company brings engineering, prototyping, regulatory support, testing, tooling, manufacturing, assembly, sterilization, and commercialization capabilities together under one roof, helping innovators move from concept to market with one team.

    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund (an internal fund with a $5k minimum) and select SPVs, while partnering with founders through capital, strategic guidance, and its broader network.

    About Pitch Deck Analysis: For founders getting ready to raise, Pitch Deck Analysis reviews your deck like an investor would, with scoring, feedback, and recommendations on what to improve before you pitch. Use code EntrepreneurRx for a free Founder Pack with five free runs.

    Afficher plus Afficher moins
    28 min
  • Lyle Small: From Color-Changing Cans to Targeted Cancer Therapy
    Nov 10 2026

    How does the inventor behind the color-changing Coors Light can end up building a new approach to cancer treatment?

    In this episode of Entrepreneur Rx, host John Shufeldt sits down with Lyle Small, Founder and CEO of Lahjavida Bio, to talk about a career built around chemistry, persistence, and solving problems other people thought were too difficult.

    Lyle is a Cornell-trained bioengineer and longtime inventor who founded Chromatic Technologies, Inc., where he spent decades developing interactive inks and coatings. One of his best-known inventions became the cold-activated technology behind the mountains that turn blue on Coors Light cans.

    But that work eventually led him somewhere entirely different.

    After hiring a chemist who had worked with a dye that selectively accumulates in cancer cells, Lyle began asking a new question: if the dye could find a tumor, could it carry a treatment with it?

    That question became the foundation for Lahjavida Bio.

    The company is developing Dye-Drug Conjugates, or DDCs, synthetic small molecules that combine a tumor-seeking near-infrared dye, a cleavable linker, and a cytotoxic payload. The concept borrows from antibody-drug conjugates, but replaces the antibody with a small-molecule dye. The goal is to carry powerful cancer drugs more selectively into tumors while keeping the payload inactive during circulation and releasing it once inside the cancer cell.

    Lahjavida’s lead compound, DDC6, pairs its dye platform with MMAE, a payload already used in several approved antibody-drug conjugates. Early preclinical studies have shown tumor growth inhibition, while DDC6 has also appeared less toxic than the unprotected chemotherapy payload in the models studied to date. The company is now working to confirm those findings across additional models and determine how broadly the platform may apply across solid tumors.

    John and Lyle dig into the science behind the platform, why tumor heterogeneity makes cancer so difficult to treat, and how DDCs could eventually make combinations of powerful therapies more practical.

    But the episode is just as much about persistence as it is about cancer.

    Lyle talks about spending more than 15 years and millions of his own dollars pursuing the technology, why he continued when others might have stopped, and what decades of invention have taught him about failure, focus, humility, and being willing to think differently.

    They also discuss a life filled with calculated risk, from building companies from scratch to rafting the Grand Canyon just weeks after breaking his back, and why Lyle believes everything he has done has prepared him for the work he is doing now.

    About Lyle Small: Lyle Small is Founder and CEO of Lahjavida Bio and founder of Chromatic Technologies, Inc. (CTI). A Cornell-trained bioengineer with more than 20 patents, he developed the color-changing technology used on Coors Light cans. He has spent more than 15 years and millions of his own dollars advancing Lahjavida’s oncology platform.

    About Lahjavida Bio: Lahjavida Bio is a Colorado-based preclinical oncology company developing Dye-Drug Conjugates to deliver therapies more selectively to tumors. Spun out of CTI in 2018, the company is advancing its lead compound, DDC6, toward an investigational new drug filing. It holds four issued U.S. patents, with additional applications pending.

    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund (an interval fund with a $5,000 minimum) and select SPVs, while partnering with founders through capital, strategic guidance, and its broader network.

    Afficher plus Afficher moins
    36 min
  • John Fees: Rethinking the Risk of Paying for College
    Oct 20 2026

    What happens when paying for college becomes a six-figure financial risk, but families have almost no safety net when something goes wrong?

    In this episode of Entrepreneur Rx, host John Shufeldt sits down with John Fees, serial entrepreneur and Co-founder and CEO of GradGuard, to talk about entrepreneurship, higher education, insurance, and the financial risks families often do not think about until it is too late.

    Fees has spent his career at the intersection of education, financial services, and technology. He previously built and sold companies to Viacom and JPMorgan Chase before co-founding Next Generation Insurance Group and launching GradGuard, a company designed to reduce the financial risks associated with college life.

    A major focus of the conversation is tuition insurance. Once a university's refund period ends, a student who has to withdraw for a covered reason may otherwise lose tuition, housing, and other academic costs already paid. GradGuard was built to provide protection against certain unexpected events and now works with more than 700 colleges and universities. Its programs have served more than 2 million students across more than 1,900 institutions.

    John and John also step back from the product itself to ask bigger questions about how America pays for education. They discuss student debt, whether the current financing system creates the right incentives, the economics of medical education, and why the cost of becoming a physician or other highly trained professional can influence career decisions long after graduation.

    The conversation then moves into entrepreneurship and insurance innovation, including why Fees believes technology and AI will pressure traditional insurance intermediaries, where specialized insurance models can still create real value, and why entrepreneurs should focus on solving problems rather than fitting into an existing industry mold.

    They close with a fascinating discussion about pattern recognition. Experience can help founders and investors recognize opportunities, but it can also create blind spots. Fees shares how his own assumptions contributed to passing on Facebook early, sparking a broader conversation about challenging what experience tells you and deliberately looking for the counterargument.

    About John Fees: John Fees is a serial entrepreneur who builds technology-enabled ventures at the intersection of financial services and education. He previously sold Y2M and Members Connect to Viacom and JPMorgan Chase, respectively, and later co-founded Next Generation Insurance Group. He holds a BS in History from Arizona State University and an MBA from Harvard Business School.

    About GradGuard: GradGuard was created around a simple problem: families can spend tens of thousands of dollars on a semester of college, yet have little protection if an unexpected illness, injury, or other covered event forces a student to withdraw. Since 2009, GradGuard has built insurance programs specifically for the risks of college life, including tuition and renters insurance. Today, the company works with more than 700 colleges and universities and has helped protect more than 2 million students across more than 1,900 institutions.

    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund ($5,000 minimum interval fund) and select SPVs, while partnering with founders through capital, strategic guidance, and its broader network.

    About My Custom Wine: My Custom Wine lets you build a wine around your own taste. Tell Augustan, its AI sommelier, what you're craving, and it can blend, taste-test, and refine a custom wine from thousands of options before it is bottled with your own blend and label. Visit mycustomwine.com to build yours.

    Afficher plus Afficher moins
    30 min
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment